Skip to content
IP + Technology Law
Home  »  News & Insights  »  Publications

Lessons From The 1st Biopharma Inter Partes Reviews | Law360

April 16, 2015  | Eli A. Loots, Ph.D.

Recently, the Patent Trial and Appeal Board issued its first set of final written decisions in three inter partes reviews relating to molecules in the large molecule biopharma space (IPR2013-00534, IPR2013- 00535 and IPR2013-00537). Biosimilar companies will no doubt be looking to these decisions as a roadmap for clearing patent landscapes for their own biosimilar products in the coming years. Read more below or download the PDF.

Lessons From The 1st Biopharma Inter Partes Reviews from Knobbe Martens Olson & Bear

Related Links

Practice Areas

Industries

News & Insights

News
Jun 2026
Jarom Kesler Comments on USPTO Ex Parte Reexamination Denial Trends in Law360
In the Law360 article “USPTO Clamping Down Reexam Bids After IPR Denials,” Knobbe Martens partner Jarom Kesler shared how a recent ruling from the U.S. Patent and Trademark Office (USPTO)...
Publications
May 2026
USPTO Director Signals Continued Pro-Patent Discretionary Denial Policy at the Patent Trial and Appeal Board
Key Takeaway: In a precedential decision in Magnolia Medical Technologies, Inc. v. Kurin, Inc., USPTO Director Squires denied IPR institution and reinforced the policy framework for discretionary denial at the...
News
May 2026
In Law360 Interview, Philip Nelson Discusses Subject Matter Eligibility Declarations in USPTO Patent Application Process
In the Law360 article “How Patent Eligibility Declarations Can Stave Off Rejection,” Knobbe Martens partner Philip Nelson discussed the practical impacts of the U.S. Patent and Trademark Office’s recent update...